uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Blomström-Lundqvist, CarinaORCID iD iconorcid.org/0000-0003-2806-3903
Alternative names
Publications (10 of 205) Show all publications
Regitz-Zagrosek, V., Roos-Hesselink, J. W., Bauersachs, J., Blomström-Lundqvist, C., Cifkova, R., De Bonis, M., . . . Warnes, C. A. (2019). 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.. Kardiologia polska, 77(3), 245-326
Open this publication in new window or tab >>2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.
Show others...
2019 (English)In: Kardiologia polska, ISSN 0022-9032, E-ISSN 1897-4279, Vol. 77, no 3, p. 245-326Article in journal (Refereed) Published
National Category
Medical and Health Sciences
Research subject
Cardiology
Identifiers
urn:nbn:se:uu:diva-381134 (URN)10.5603/KP.2019.0049 (DOI)30912108 (PubMedID)
Available from: 2019-04-04 Created: 2019-04-04 Last updated: 2019-04-04
Lip, G. Y. .., Collet, J.-P., Haude, M., Byrne, R., Chung, E. H., Fauchier, L., . . . Huber, K. (2019). 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace, 21(2), 192-+
Open this publication in new window or tab >>2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)
Show others...
2019 (English)In: Europace, ISSN 1099-5129, E-ISSN 1532-2092, Vol. 21, no 2, p. 192-+Article in journal (Refereed) Published
Abstract [en]

In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Since publication of this document, additional data from observational cohorts, randomized controlled trials, and percutaneous interventions as well as new guidelines have been published. Moreover, new drugs and devices/interventions are also available, with an increasing evidence base. The approach to managing AF has also evolved towards a more integrated or holistic approach. In recognizing these advances since the last consensus document, EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), proposed a focused update, to include the new data, with the remit of comprehensively reviewing the available evidence and publishing a focused update consensus document on the management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions, and providing up-to-date consensus recommendations for use in clinical practice.

Keywords
European Heart Rhythm Association, Consensus document, Position paper, Atrial fibrillation, Acute coronary syndrome, Coronary artery disease, Myocardial infarction, Percutaneous coronary intervention, Stent, Antithrombotic therapy, Antiplatelet agents, Anticoagulation, Vitamin K antagonists, Non-vitamin K antagonist oral anticoagulants, Low molecular weight heparin, Parenteral anticoagulants, Left atrial appendage occlusion, Stroke, Thromboembolism, Thrombosis, Bleeding
National Category
Cardiac and Cardiovascular Systems
Research subject
Cardiology
Identifiers
urn:nbn:se:uu:diva-365929 (URN)10.1093/europace/euy174 (DOI)000462550800006 ()30052888 (PubMedID)
Note

Blomström-Lundqvist, Carina & Stefan, James is part of: ESC Scientific Document Group.

For complete list of authors see http://dx.doi.org/10.1093/europace/euy174

Available from: 2018-11-15 Created: 2018-11-15 Last updated: 2019-04-29Bibliographically approved
Brugada, J., Katritsis, D. G., Arbelo, E., Arribas, F., Bax, J. J., Blomström-Lundqvist, C., . . . Zaza, A. (2019). 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).. European Heart Journal, Article ID ehz467.
Open this publication in new window or tab >>2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).
Show others...
2019 (English)In: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, article id ehz467Article in journal (Refereed) Epub ahead of print
Keywords
Guidelines, ablation, arrhythmia, atrioventricular, flutter, focal, junctional, macro–re-entrant, nodal, pre-excitation, re-entrant, supraventricular, tachycardia
National Category
Medical and Health Sciences
Research subject
Cardiology
Identifiers
urn:nbn:se:uu:diva-393493 (URN)10.1093/eurheartj/ehz467 (DOI)31504425 (PubMedID)
Available from: 2019-09-23 Created: 2019-09-23 Last updated: 2019-09-23
Holmqvist, F., Kesek, M., Englund, A., Blomström-Lundqvist, C., Karlsson, L. O., Kennebäck, G., . . . Insulander, P. (2019). A decade of catheter ablation of cardiac arrhythmias in Sweden: ablation practices and outcomes. European Heart Journal, 40(10), 820-830
Open this publication in new window or tab >>A decade of catheter ablation of cardiac arrhythmias in Sweden: ablation practices and outcomes
Show others...
2019 (English)In: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 40, no 10, p. 820-830Article in journal (Refereed) Published
Abstract [en]

Aims: Catheter ablation is considered the treatment of choice for many tachyarrhythmias, but convincing 'real-world' data on efficacy and safety are lacking. Using Swedish national registry data, the ablation spectrum, procedural characteristics, as well as ablation efficacy and reported adverse events are reported.

Methods and Results: Consecutive patients (≥18 years of age) undergoing catheter ablation in Sweden between 01 January 2006 and 31 December 2015 were included in the study. Follow-up (repeat ablation and vital status) was collected through 31 December 2016. A total of 26 642 patients (57 ± 15 years, 62% men), undergoing a total of 34 428 ablation procedures were included in the study. In total, 4034 accessory pathway/Wolff-Parkinson-White syndrome (12%), 7358 AV-nodal re-entrant tachycardia (21%), 1813 atrial tachycardia (5.2%), 5481 typical atrial flutter (16%), 11 916 atrial fibrillation (AF, 35%), 2415 AV-nodal (7.0%), 581 premature ventricular contraction (PVC, 1.7%), and 964 ventricular tachycardia (VT) ablations (2.8%) were performed. Median follow-up time was 4.7 years (interquartile range 2.7-7.0). The spectrum of treated arrhythmias changed over time, with a gradual increase in AF, VT, and PVC ablation (P < 0.001). Decreasing procedural times and utilization of fluoroscopy with time, were seen for all arrhythmia types. The rates of repeat ablation differed between ablation types, with the highest repeat ablation seen in AF (41% within 3 years). The rate of reported adverse events was low (n = 595, 1.7%). Death in the immediate period following ablation was rare (n = 116, 0.34%).

Conclusion: Catheter ablations have shifted towards more complex procedures over the past decade. Fluoroscopy time has markedly decreased and the efficacy of catheter ablation seems to improve for AF.

Keywords
Catheter ablation, Adverse events, Outcome
National Category
Cardiac and Cardiovascular Systems
Research subject
Cardiology
Identifiers
urn:nbn:se:uu:diva-367225 (URN)10.1093/eurheartj/ehy709 (DOI)000461141900010 ()30452631 (PubMedID)
Funder
Swedish Association of Local Authorities and RegionsThe Crafoord FoundationSwedish Heart Lung Foundation
Available from: 2018-11-29 Created: 2018-11-29 Last updated: 2019-04-12Bibliographically approved
Stabile, G., Trines, S. A. & Blomström-Lundqvist, C. (2019). Atrial fibrillation history impact on catheter ablation outcome [Letter to the editor]. Pacing and Clinical Electrophysiology, 42(6), 759-759
Open this publication in new window or tab >>Atrial fibrillation history impact on catheter ablation outcome
2019 (English)In: Pacing and Clinical Electrophysiology, ISSN 0147-8389, E-ISSN 1540-8159, Vol. 42, no 6, p. 759-759Article in journal, Letter (Other academic) Published
National Category
Cardiac and Cardiovascular Systems
Research subject
Cardiology
Identifiers
urn:nbn:se:uu:diva-378579 (URN)10.1111/pace.13645 (DOI)000472195600034 ()30828818 (PubMedID)
Funder
AstraZeneca
Available from: 2019-03-07 Created: 2019-03-07 Last updated: 2019-08-26Bibliographically approved
Stabile, G., Trines, S. A., Arbelo, E., Dagres, N., Brugada, J., Kautzner, J., . . . Blomström-Lundqvist, C. (2019). Atrial fibrillation history impact on catheter ablation outcome: Findings from the ESC-EHRA atrial fibrillation ablation long-term registry. Pacing and Clinical Electrophysiology, 42(3), 313-320
Open this publication in new window or tab >>Atrial fibrillation history impact on catheter ablation outcome: Findings from the ESC-EHRA atrial fibrillation ablation long-term registry
Show others...
2019 (English)In: Pacing and Clinical Electrophysiology, ISSN 0147-8389, E-ISSN 1540-8159, Vol. 42, no 3, p. 313-320Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Atrial fibrillation (AF) promotes atrial remodeling that in turn promote AF perpetuation. The aim of our study was to investigate the impact of AF history length on one-year outcome of AF catheter ablation in a cohort of patients enrolled in the Atrial Fibrillation Ablation Registry.

METHODS: We described the real-life clinical epidemiology, therapeutic strategies and the short- and mid-term outcomes of 1948 patients (71.9% with paroxysmal AF) undergoing AF ablation procedures, stratified according to AF history duration (< 2 years or ≥ 2 years).

RESULTS: The mean AF history duration was 46,2±57,4 months, 592 patients had an AF history duration < 2 years (mean 10,2±5,9 months), and 1356 patients ≥ 2 years (mean 75,5±63,5 months) (P < 0.001). Patients with AF history duration < 2 years were younger, had a lower incidence of hypertension, coronary artery disease, hypertrophic cardiomyopathy and had a lower CHA2 DS2 -VaSc Score. At one year, the logrank test showed a lower incidence of AF recurrence in patients with AF history duration < 2 years (28.9%) than in patients with AF history duration ≥ 2 years (34.0%) (P = 0.037). AF history duration ≥ 2 years, overall ablation procedure duration, hypertension and chronic kidney disease were all predictors of recurrences after the blanking period.

CONCLUSIONS: In this multicenter registry, performing catheter ablation in patients with an AF history ≥ 2 years was associated with higher rates of AF recurrences at one year. Since cumulative time in AF in not necessarily equivalent to AF history, its role remains to be clarified.

Keywords
Atrial fibrillation, Atrial fibrillation duration, Catheter ablation, Mid-term outcome, recurrence predictors
National Category
Cardiac and Cardiovascular Systems
Research subject
Cardiology
Identifiers
urn:nbn:se:uu:diva-373390 (URN)10.1111/pace.13600 (DOI)000460951100005 ()30632196 (PubMedID)
Funder
AstraZeneca
Available from: 2019-01-14 Created: 2019-01-14 Last updated: 2019-04-11Bibliographically approved
Bertaglia, E., Blank, B., Blomström-Lundqvist, C., Brandes, A., Cabanelas, N., Dan, G.-A., . . . Kirchhof, P. (2019). Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence.. Europace, Article ID euz172.
Open this publication in new window or tab >>Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence.
Show others...
2019 (English)In: Europace, ISSN 1099-5129, E-ISSN 1532-2092, article id euz172Article in journal (Refereed) Epub ahead of print
Abstract [en]

Self-terminating atrial arrhythmias are commonly detected on continuous rhythm monitoring, e.g. by pacemakers or defibrillators. It is unclear whether the presence of these arrhythmias has therapeutic consequences. We sought to summarize evidence on the prevalence of atrial high-rate episodes (AHREs) and their impact on risk of stroke. We performed a comprehensive, tabulated review of published literature on the prevalence of AHRE. In patients with AHRE, but without atrial fibrillation (AF), we reviewed the stroke risk and the potential risk/benefit of oral anticoagulation. Atrial high-rate episodes are found in 10-30% of AF-free patients. Presence of AHRE slightly increases stroke risk (0.8% to 1%/year) compared with patients without AHRE. Atrial high-rate episode of longer duration (e.g. those >24 h) could be associated with a higher stroke risk. Oral anticoagulation has the potential to reduce stroke risk in patients with AHRE but is associated with a rate of major bleeding of 2%/year. Oral anticoagulation is not effective in patients with heart failure or survivors of a stroke without AF. It remains unclear whether anticoagulation is effective and safe in patients with AHRE. Atrial high-rate episodes are common and confer a slight increase in stroke risk. There is true equipoise on the best way to reduce stroke risk in patients with AHRE. Two ongoing trials (NOAH-AFNET 6 and ARTESiA) will provide much-needed information on the effectiveness and safety of oral anticoagulation using non-vitamin K antagonist oral anticoagulants in patients with AHRE.

Keywords
Anticoagulation, Atrial fibrillation, Atrial high-rate episodes, Continuous monitoring, Pacemaker, Stroke
National Category
Medical and Health Sciences
Research subject
Cardiology
Identifiers
urn:nbn:se:uu:diva-393491 (URN)10.1093/europace/euz172 (DOI)31377792 (PubMedID)
Available from: 2019-09-23 Created: 2019-09-23 Last updated: 2019-09-23
Kalarus, Z., Svendsen, J. H., Capodanno, D., Dan, G.-A., De Maria, E., Gorenek, B., . . . Berti, S. (2019). Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA).. Europace, Article ID euz163.
Open this publication in new window or tab >>Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA).
Show others...
2019 (English)In: Europace, ISSN 1099-5129, E-ISSN 1532-2092, article id euz163Article in journal (Refereed) Epub ahead of print
Abstract [en]

Despite major therapeutic advances over the last decades, complex supraventricular and ventricular arrhythmias (VAs), particularly in the emergency setting or during revascularization for acute myocardial infarction (AMI), remain an important clinical problem. Although the incidence of VAs has declined in the hospital phase of acute coronary syndromes (ACS), mainly due to prompt revascularization and optimal medical therapy, still up to 6% patients with ACS develop ventricular tachycardia and/or ventricular fibrillation within the first hours of ACS symptoms. Despite sustained VAs being perceived predictors of worse in-hospital outcomes, specific associations between the type of VAs, arrhythmia timing, applied treatment strategies and long-term prognosis in AMI are vague. Atrial fibrillation (AF) is the most common supraventricular tachyarrhythmia that may be asymptomatic and/or may be associated with rapid haemodynamic deterioration requiring immediate treatment. It is estimated that over 20% AMI patients may have a history of AF, whereas the new-onset arrhythmia may occur in 5% patients with ST elevation myocardial infarction. Importantly, patients who were treated with primary percutaneous coronary intervention for AMI and developed AF have higher rates of adverse events and mortality compared with subjects free of arrhythmia. The scope of this position document is to cover the clinical implications and pharmacological/non-pharmacological management of arrhythmias in emergency presentations and during revascularization. Current evidence for clinical relevance of specific types of VAs complicating AMI in relation to arrhythmia timing has been discussed.

Keywords
Acute myocardial infarction, Atrial fibrillation, Reperfusion, Ventricular fibrillation, Ventricular tachycardia
National Category
Medical and Health Sciences
Research subject
Cardiology
Identifiers
urn:nbn:se:uu:diva-393489 (URN)10.1093/europace/euz163 (DOI)31353412 (PubMedID)
Available from: 2019-09-23 Created: 2019-09-23 Last updated: 2019-09-23
Normand, C., Linde, C., Bogale, N., Blomström-Lundqvist, C., Auricchio, A., Stellbrink, C., . . . Dickstein, K. (2019). Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice?-findings from the ESC CRT Survey II. Europace, 21(6), 918-927
Open this publication in new window or tab >>Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice?-findings from the ESC CRT Survey II
Show others...
2019 (English)In: Europace, ISSN 1099-5129, E-ISSN 1532-2092, Vol. 21, no 6, p. 918-927Article in journal (Refereed) Published
Abstract [en]

AIMS: The decision to implant a cardiac resynchronization therapy pacemaker (CRT-P) or a cardiac resynchronization therapy defibrillator (CRT-D) may be challenging. There are no clear guideline recommendations as no randomized study of cardiac resynchronization therapy (CRT) has been designed to compare the effects of CRT-P with those of CRT-D on patients' outcomes. In the CRT Survey II, we studied patient and implantation centre characteristics associated with the choice of CRT-P vs. CRT-D.

METHODS AND RESULTS: Clinical practice data from 10 692 patients undergoing CRT implantation of whom 7467 (70%) patients received a CRT-D and 3225 (30%) received a CRT-P across 42 ESC countries were collected and analysed between October 2015 and January 2017. Factors favouring the selection of CRT-P implantation included age >75 years, female gender, non-ischaemic heart failure (HF) aetiology, New York Heart Association functional Class III/IV symptoms, left ventricular ejection fraction >25%, atrial fibrillation, atrioventricular (AV) block II/III, and implantation in a university hospital.

CONCLUSION: In a large cohort from the CRT Survey II, we found that patients allocated to receive CRT-P exhibited particular phenotypes with more symptomatic HF, more frequent comorbidities, advanced age, female gender, non-ischaemic HF aetiology, atrial fibrillation, and evidence of AV block. There were substantial differences in the proportion of patients allocated to receive CRT-P vs. CRT-D between countries.

Keywords
Cardiac resynchronization therapy, Cardiac resynchronization therapy defibrillator, Cardiac resynchronization therapy pacemaker, Heart failure, Implantable cardioverter-defibrillator
National Category
Cardiac and Cardiovascular Systems
Research subject
Cardiology
Identifiers
urn:nbn:se:uu:diva-385414 (URN)10.1093/europace/euz002 (DOI)000471244000019 ()31157387 (PubMedID)
Available from: 2019-06-13 Created: 2019-06-13 Last updated: 2019-07-05Bibliographically approved
Temporelli, P. L., Tilz, R. R., Arbelo, E., Dagres, N., Laroche, C., Crijns, H. J., . . . Tavazzi, L. (2019). Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association. [Letter to the editor]. European Journal of Heart Failure, 21(5), 690-693
Open this publication in new window or tab >>Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association.
Show others...
2019 (English)In: European Journal of Heart Failure, ISSN 1388-9842, E-ISSN 1879-0844, Vol. 21, no 5, p. 690-693Article in journal, Letter (Other academic) Published
National Category
Cardiac and Cardiovascular Systems
Research subject
Cardiology
Identifiers
urn:nbn:se:uu:diva-380256 (URN)10.1002/ejhf.1458 (DOI)000471307000023 ()30896056 (PubMedID)
Available from: 2019-03-25 Created: 2019-03-25 Last updated: 2019-07-02Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0003-2806-3903

Search in DiVA

Show all publications